Piribedil
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00591994)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 3 Sponsor(trial)
Mechanism of action
- Dopamine D3 receptorAGONIST
DRD3 agonist
- Dopamine D2 receptorAGONIST
DRD2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1- Mol. weight
- 298.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1371770 ↗
- ChEMBLCHEMBL1256997 ↗
Also known as
- et-495
- et-495
- et-495
- eu 4200
- eu-4200
- eu-4200
- eu-4200
- piribedil
- piribedil
- piribedil
- piribedil
- piribedil
- piribedil
- piribedil hcl
- piribedil hydrochloride
- piribedil maleate
- piribedil methanesulfonate
- piribedil methanesulfonate
- piribedil methanesulfonate
- piribedil methanesulfonate
- piribedil methanesulfonate
- trivastal
- trivastal
- trivastal
- trivastal lp
- trivastan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01007864 | Phase 3 | Jan 1, 2010 | Desitin Arzneimittel GmbH, FGK Clinical Research GmbH |
| NCT00591994 | N/A | Nov 1, 2006 | Faculdade de Medicina de Valenca, Fluminense Federal University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Desitin Arzneimittel GmbH | For profit | 1 | 1 | 1 | 2010 |
| Faculdade de Medicina de Valenca | Academic/Hospital | 1 | 1 | 1 | 2006 |
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2010 |
| Fluminense Federal University | Academic/Hospital | 1 | 0 | 1 | 2006 |
4 organizations
Page 1 / 1